Institution
University of London
Education•London, United Kingdom•
About: University of London is a education organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Public health. The organization has 44838 authors who have published 88086 publications receiving 4002499 citations. The organization is also known as: London University & Lond..
Topics: Population, Public health, Health care, Malaria, Health policy
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Major research challenges remain in relation to measurement issues, comorbidity, gender differences, cognitive processing, nature–nurture interplay, heterotypic continuity, continuities between normal variations and disorders, developmental programming, and therapeutic mechanisms in effective treatments.
Abstract: The defining features of developmental psychopathology concepts include attention to the understanding of causal processes, appreciation of the role of developmental mechanisms, and consideration of continuities and discontinuities between normality and psychopathology. Accomplishments with respect to these issues are reviewed in relation to attachment disorders, antisocial behavior, autism, depressive disorder, schizophrenia, and intellectual development. Major research challenges remain in relation to measurement issues, comorbidity, gender differences, cognitive processing, nature-nurture interplay, heterotypic continuity, continuities between normal variations and disorders, developmental programming, and therapeutic mechanisms in effective treatments.
841 citations
••
TL;DR: Mitigation of climate change by reducing the use of fossil fuels and increasing a number of uses of the renewable energy technologies should improve health in the near-term by reducing exposure to air pollution.
834 citations
••
TL;DR: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk ofNonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
Abstract: Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
834 citations
••
TL;DR: The WHO–UNICEF–Lancet Commission presents a candid assessment of the threats children face and the sombre implications for their future, and emphasises the role of community engagement in promoting the health and development of the world’s children.
830 citations
••
Joan B. Soriano1, Parkes J Kendrick2, Katherine R. Paulson2, Vinay Gupta2 +311 more•Institutions (178)
TL;DR: It is shown that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990.
829 citations
Authors
Showing all 44949 results
Name | H-index | Papers | Citations |
---|---|---|---|
George Davey Smith | 224 | 2540 | 248373 |
Karl J. Friston | 217 | 1267 | 217169 |
Nicholas J. Wareham | 212 | 1657 | 204896 |
David Miller | 203 | 2573 | 204840 |
Raymond J. Dolan | 196 | 919 | 138540 |
Peter J. Barnes | 194 | 1530 | 166618 |
Michael Marmot | 193 | 1147 | 170338 |
Michael Rutter | 188 | 676 | 151592 |
Terrie E. Moffitt | 182 | 594 | 150609 |
Tony Hunter | 175 | 593 | 124726 |
Chris D. Frith | 173 | 524 | 130472 |
David Baker | 173 | 1226 | 109377 |
Barry Halliwell | 173 | 662 | 159518 |
Didier Raoult | 173 | 3267 | 153016 |
Feng Zhang | 172 | 1278 | 181865 |